Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells.

Graham MK, Kim J, Da J, Brosnan-Cashman JA, Rizzo A, Baena Del Valle JA, Chia L, Rubenstein M, Davis C, Zheng Q, Cope L, Considine M, Haffner MC, De Marzo AM, Meeker AK, Heaphy CM.

Mol Cancer Res. 2019 Dec;17(12):2480-2491. doi: 10.1158/1541-7786.MCR-19-0654. Epub 2019 Oct 14.

PMID:
31611308
2.

Telomere alterations in neurofibromatosis type 1-associated solid tumors.

Rodriguez FJ, Graham MK, Brosnan-Cashman JA, Barber JR, Davis C, Vizcaino MA, Palsgrove DN, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noë M, Wood LD, Pratilas CA, Morris CD, Belzberg A, Blakeley J, Heaphy CM.

Acta Neuropathol Commun. 2019 Aug 28;7(1):139. doi: 10.1186/s40478-019-0792-5.

3.

Genetic alterations associated with ALTered telomeres.

Brosnan-Cashman JA, Graham MK, Heaphy CM.

Oncotarget. 2018 Sep 18;9(73):33739-33740. doi: 10.18632/oncotarget.26111. eCollection 2018 Sep 18. No abstract available.

4.

ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner.

Brosnan-Cashman JA, Yuan M, Graham MK, Rizzo AJ, Myers KM, Davis C, Zhang R, Esopi DM, Raabe EH, Eberhart CG, Heaphy CM, Meeker AK.

PLoS One. 2018 Sep 18;13(9):e0204159. doi: 10.1371/journal.pone.0204159. eCollection 2018.

5.

Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.

Rodriguez FJ, Brosnan-Cashman JA, Allen SJ, Vizcaino MA, Giannini C, Camelo-Piragua S, Webb M, Matsushita M, Wadhwani N, Tabbarah A, Hamideh D, Jiang L, Chen L, Arvanitis LD, Alnajar HH, Barber JR, Rodríguez-Velasco A, Orr B, Heaphy CM.

Brain Pathol. 2019 Jan;29(1):126-140. doi: 10.1111/bpa.12646. Epub 2018 Oct 17.

PMID:
30192422
6.

Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association.

Palsgrove DN, Brosnan-Cashman JA, Giannini C, Raghunathan A, Jentoft M, Bettegowda C, Gokden M, Lin D, Yuan M, Lin MT, Heaphy CM, Rodriguez FJ.

Mod Pathol. 2018 Dec;31(12):1787-1800. doi: 10.1038/s41379-018-0103-x. Epub 2018 Jul 4.

7.

The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma.

Diplas BH, He X, Brosnan-Cashman JA, Liu H, Chen LH, Wang Z, Moure CJ, Killela PJ, Loriaux DB, Lipp ES, Greer PK, Yang R, Rizzo AJ, Rodriguez FJ, Friedman AH, Friedman HS, Wang S, He Y, McLendon RE, Bigner DD, Jiao Y, Waitkus MS, Meeker AK, Yan H.

Nat Commun. 2018 May 25;9(1):2087. doi: 10.1038/s41467-018-04448-6.

8.

Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer.

Koschmann C, Nunez FJ, Mendez F, Brosnan-Cashman JA, Meeker AK, Lowenstein PR, Castro MG.

Cancer Res. 2017 Jan 15;77(2):227-233. doi: 10.1158/0008-5472.CAN-16-2301. Epub 2017 Jan 6. Review.

9.

Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.

Kim JY, Brosnan-Cashman JA, An S, Kim SJ, Song KB, Kim MS, Kim MJ, Hwang DW, Meeker AK, Yu E, Kim SC, Hruban RH, Heaphy CM, Hong SM.

Clin Cancer Res. 2017 Mar 15;23(6):1598-1606. doi: 10.1158/1078-0432.CCR-16-1147. Epub 2016 Sep 23.

10.

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.

Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, Krasinkiewicz J, Doherty R, Lemons R, Brosnan-Cashman JA, Li Y, Roh S, Zhao L, Appelman H, Ferguson D, Gorbunova V, Meeker A, Jones C, Lowenstein PR, Castro MG.

Sci Transl Med. 2016 Mar 2;8(328):328ra28. doi: 10.1126/scitranslmed.aac8228.

Supplemental Content

Loading ...
Support Center